Strategic Asset Sale MiRus recently announced the sale of assets to Boston Scientific for 3 billion dollars, with potential follow-on acquisition of the TAVR business. This indicates a significant strategic shift and validation of MiRus technology, presenting an opportunity to engage Boston Scientific’s ecosystem or explore parallel collaborations with MiRus on remaining platforms and adjacencies.

Cervical and Upper Spine Focus Breakthrough Device Designation and prior launches highlight a strong emphasis on rhenium alloy based solutions for cervical and upper thoracic spine conditions. This creates sales opportunities with hospitals and surgeons specializing in complex spine therapies, and potential upsell to integrated pre/intra/post-operative platforms.

Expandable Precision Systems Recent FDA 510(k) clearance and launches of IO Expandable Wedge Osteotomy System and adjustable implant technology underscore a trend toward intraoperative precision and customizable correction. Targets include foot and ankle surgeons and institutions adopting modular, adjustable implants for greater surgical control.

Remote Monitoring Advantage MiRus offers remote physiologic monitoring platforms as part of its continuum-of-care solution. This capability aligns with value-based care initiatives and payer-driven outcomes, suggesting cross-sell opportunities to current customers or expanded deployments with health systems seeking integrated digital health and device solutions.

Growth Capital and Market Presence With substantial funding history and a revenue range in the tens of millions, MiRus is positioned for expansion; identify collaboration or channel opportunities with larger spine and orthopedics players, distributors, or CRO/advisory partners to accelerate adoption of its MoRe alloy products and expansion systems.